Pediatric Autoimmune Disease Progression And Early Biomarker Identification Through Multi-Omics Approaches

Abstract

Background: Autoimmune diseases in children, including juvenile idiopathic arthritis, pediatric systemic lupus erythematosus, type 1 diabetes, and inflammatory bowel disease, are characterized by immune dysregulation and progressive tissue damage. Nonetheless, the heterogeneity of clinical presentation and the lack of reliable predictive biomarkers still make early diagnosis and timely intervention difficult. Recent advances in multi-omics technologies have facilitated the comprehensive investigation of the molecular mechanisms involved in disease progression. Objective: The aim of the current study is to investigate the potential of multi-omics approaches for early biomarker discovery and disease progression prediction in pediatric autoimmune disorders. Methodology: We performed an in-depth analysis of genomics, transcriptomics, proteomics, metabolomics and epigenomics datasets from cohorts of paediatric autoimmune disease. We used bioinformatics and machine learning techniques to identify molecular signatures associated with disease onset, progression and therapeutic response. Performance metrics were biomarker detection accuracy, predictive sensitivity and specificity, and disease progression assessment.  Findings: The results showed that the multi-omics integration could achieve a biomarker identification accuracy of 94.2%, sensitivity of 92.8% and specificity of 91.6%. Early biomarker-based prediction improved disease progression assessment by 38% and treatment stratification efficiency by 34% allowing for earlier clinical intervention. Conclusion: Multi-omics strategies greatly enhance the identification of early biomarkers and the prediction of disease progression in pediatric autoimmune diseases. Integrating molecular data from multiple layers can support precision medicine approaches, facilitate personalized treatment planning and improve long-term clinical outcomes.